Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
NCT ID: NCT02687373
Last Updated: 2019-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
337 participants
INTERVENTIONAL
2016-07-21
2018-08-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intermittent Preventive Treatment With Antimalarials in Kenyan Infants
NCT00111163
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
NCT00866619
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
NCT02471378
A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccine in Young Children Across Sub-Saharan Africa
NCT03855995
A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine
NCT02374450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Vaccination will begin in the 5-9 year age group at a dosage of 4.5 x10\^5 PfSPZ. A single vaccination will be administered by DVI to each of 12 participants aged 5-9 years (inclusive) of age, 8 receiving PfSPZ vaccine and 4 participants receiving NS placebo by DVI, with treatment allocation randomized and double-blind. Once the initial dose has been shown to be well tolerated and without safety concerns, the next higher dose of 9.0 x 10\^5 PfSPZ will be administered to a second group of 5-9 year olds. Once this has been shown to be well tolerated and without safety concerns, the highest dose of 1.8 x 10\^6 PfSPZ will be given to a third group of 5-9 year olds and concurrently the lowest dose (1.35 x10\^5) will be given to a same-sized group of younger children aged 13-59 months. Two weeks later, this dose will be escalated to 2.7 x10\^5 PfSPZ in a second group of children aged 13-59 months. Only once this dose is shown to be well-tolerated and without safety concerns will PfSPZ Vaccine, at the lowest dose, be given to infants aged 5 - 12 months. Within each age group, dosages will increase stepwise until they reach 1.8 x 10\^6 PfSPZ, with the initiation of each group staggered by at least 2 weeks, provided that no safety thresholds are surpassed. In each dosage level, the PfSPZ Vaccine or placebo will be provided to a limited number of participants each day (e.g. 3 participants from one age group on days 1 through 4). The PfSPZ Vaccine dose will only be increased to the next dose level when safety has been assessed in subjects of the first group. The same procedures will be followed for all doses. Children in all age groups who are enrolled to receive the 2 highest doses, i.e. 9.0 x 10\^5 or 1.8 x 10\^6 PfSPZ, or placebo, will receive a second vaccination of the same dose after 8 weeks, provided the first vaccination at this dose level did not show safety signals.
Part 2: Safety and Efficacy Part of this study will be conducted in the outpatient areas of Siaya County Referral Hospital, a large referral hospital in western Kenya and in Wagai dispensary. A maximum of 416 infants from 5 M to 12 M inclusive at vaccination will be enrolled into this safety and efficacy trial and randomized to receive PfSPZ Vaccine at a dose determined during Part 1 of the trial (dose escalation), but likely to be 4.5x10\^5, 9.0 x10\^5and 1.8 x 10\^6 administered x 3 doses ; and NS placebo administered x 3 doses, all by DVI administered at 8 week intervals.
Participants (N = 416, with 104 in each study arm) will be randomly assigned in a double blinded fashion to receive one of the following PfSPZ Vaccine regimes:
Group 1 (N=104): The highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10\^6 PfSPZ per dose.
Group 2 (N=104): The second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10\^5 PfSPZ per dose.
Group 3 (N=104): A lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10\^5 PfSPZ per dose.
Group 4 (N=104): A placebo arm, will receive NS by DVI, 3 times at 8 week intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Grp 1A - PfSPZ Vaccine
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 1A - Normal Saline
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 1B - PfSPZ Vaccine
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 1B - Normal Saline
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 1C - PfSPZ Vaccine
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 1C - Normal Saline
Children aged 5-9 years (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 2A - PfSPZ Vaccine
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 1.35 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 2A - Normal Saline
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 2B - PfSPZ Vaccine
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 2.7 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 2B - Normal Saline
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 2C - PfSPZ Vaccine
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 2C - Normal Saline
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 2D - PfSPZ Vaccine
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 2D - Normal Saline
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 2E - PfSPZ Vaccine
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 2E - Normal Saline
Children aged 13-59 months (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 3A - PfSPZ Vaccine
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 1.35 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 3A - Normal Saline
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 3B - PfSPZ Vaccine
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 2.7 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 3B - Normal Saline
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 3C - PfSPZ Vaccine
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=8; Dose of 4.5 x 10\^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 3C - Normal Saline
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 3D - PfSPZ Vaccine
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=8; Two doses of 9.0 x 10\^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 3D - Normal Saline
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 1: Grp 3E - PfSPZ Vaccine
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=8; Two doses of 1.8 x 10\^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 1: Grp 3E - Normal Saline
Children aged 5-12 months (inclusive) of age will be enrolled in this group.
N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals.
Normal Saline
0.9% Sodium chloride
Part 2: Group 1 - PfSPZ Vaccine
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10\^6 PfSPZ per dose.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 2: Group 2 - PfSPZ Vaccine
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10\^5 PfSPZ per dose.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 2: Group 3 - PfSPZ Vaccine
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10\^5 PfSPZ per dose.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Part 2: Group 4 - Normal Saline
Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.
N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals.
Normal Saline
0.9% Sodium chloride
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PfSPZ Vaccine
Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
Normal Saline
0.9% Sodium chloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV negative
* Able to participate for the duration of the study.
* Parents/guardians over the age of 18 years able and willing to provide informed consent/permission. The consent/permission will be in writing. For adult parents or guardians who are illiterate, an impartial witness can sign the consent/permission form on behalf of the parent and the parent/guardian will provide a thumb print.
Exclusion Criteria
* Refusal of HIV testing
* Elevated ALT (liver function test) ≥2x ULN ( ALT \>84 U/L)
* Abnormal hematological parameters defined as: hemoglobin \< 8 g/dl, WBC \<1500 / mm3, neutrophils \<750/ mm3, platelet count \<75.000/ mm3
* Abnormal renal function test with creatinine \>0.9 mg/dL
* Known sickle cell disease and other inherited blood cell disorders like thalassemia and G6PD deficiency
* Current use of systemic immunosuppressant pharmacotherapy
* Current significant medical condition (cardiac, hepatic, renal, or hematological) or evidence of any other serious underlying medical condition identified by medical history, physical examination, or laboratory examination
* History of a splenectomy
* History of neurologic disorder (including seizures, other than uncomplicated febrile seizures)
* Known allergy to any component of the vaccine formulation, history of anaphylactic response to mosquito-bites, or known allergy to first or second line anti-malarials used to treat malaria
* Plan to participate in another investigational vaccine/drug research during or within 1 month of this study end
* Prior participation in a malaria vaccine trial
* Participation in the PfSPZ Vaccine Trial Part 1 (for Part 2 only)
* History of any other illness or condition which, in the investigator's judgment, may substantially increase the risk associated with the subject's participation in the protocol or compromise the scientific objectives
* Child/orphan in institutional care
5 Months
9 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kenya Medical Research Institute
OTHER
Centers for Disease Control and Prevention
FED
National Institutes of Health (NIH)
NIH
University of Maryland
OTHER
Sanaria Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martina Oneko, MD
Role: PRINCIPAL_INVESTIGATOR
Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Global Health Research, KEMRI
Kisian, Siaya County, Kenya
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oneko M, Steinhardt LC, Yego R, Wiegand RE, Swanson PA, Kc N, Akach D, Sang T, Gutman JR, Nzuu EL, Dungani A, Kim Lee Sim B, Oloo PN, Otieno K, Bii DK, Billingsley PF, James ER, Kariuki S, Samuels AM, Jongo S, Chebore W, Abdulla S, Daubenberger C, Mpina M, Styers D, Potter GE, Abarbanell G, Richie TL, Hoffman SL, Seder RA. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat Med. 2021 Sep;27(9):1636-1645. doi: 10.1038/s41591-021-01470-y. Epub 2021 Sep 13.
Oneko M, Cherop YR, Sang T, Gutman JR, Wiegand R, Nyang'au EM, Odila AD, Akach D, Hamel MJ, Samuels AM, Kariuki S, Abebe Y, Nzuu EL, Wijayalath W, James ER, Sim BKL, Billingsley PF, Richie TL, Hoffman SL, Seder RA, Steinhardt LC. Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya. Vaccine. 2020 Jun 15;38(29):4592-4600. doi: 10.1016/j.vaccine.2020.05.008. Epub 2020 May 19.
Steinhardt LC, Richie TL, Yego R, Akach D, Hamel MJ, Gutman JR, Wiegand RE, Nzuu EL, Dungani A, Kc N, Murshedkar T, Church LWP, Sim BKL, Billingsley PF, James ER, Abebe Y, Kariuki S, Samuels AM, Otieno K, Sang T, Kachur SP, Styers D, Schlessman K, Abarbanell G, Hoffman SL, Seder RA, Oneko M. Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya. Clin Infect Dis. 2020 Aug 14;71(4):1063-1071. doi: 10.1093/cid/ciz925.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDC IRB Protocol #6787
Identifier Type: OTHER
Identifier Source: secondary_id
KEMRI/SERU/CGHR/017/3129
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.